ClinicalTrials.gg
CompletedNCT03725722Updated Mar 12, 2025Results posted

Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over an 8-week Treatment Period in Adult Subjects With Atopic Dermatitis.

A Phase 2 interventional study of Delgocitinib cream and Delgocitinib cream vehicle in Atopic Dermatitis, sponsored by LEO Pharma. Completed at 31 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-03-12.

Sponsored by LEO Pharma · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
251
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 36 studies in Dermatitis, Atopic by LEO Pharma — 1 open to participants now, 1 under way, 1 of them phase 3. Dermatitis, Atopic · LEO Pharma.

Enrollment
8th of 34
251 · median 70
Started
2018
with 7 others
Phase 2
8 of 36
none open now
Registered
25th of 36
by date

Among the 36 studies in Dermatitis, Atopic by LEO Pharma, this one is the 8th largest by enrollment of the 34 interventional ones that give a count, is one of 8 that started in 2018, is one of 8 in phase 2, and was the 25th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

1 of the 36 studies in Dermatitis, Atopic by LEO Pharma is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Dermatitis, Atopic by LEO Pharma, or all of them as a file.
02

Study summary

This is a double-blind, multi-centre, randomised, 5-arm, vehicle-controlled, parallel-group trial. The trial is designed to establish a dose-response signal and investigate the efficacy and safety of delgocitinib cream in the treatment of adult subjects with mild to severe atopic dermatitis (AD).

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age 18 years and above.
  • Diagnosis of AD as defined by the Hanifin and Rajka 1980 criteria for AD.
  • History of AD for ≥1 year.
  • AD involvement of 5-50% treatable body surface area at screening and at baseline (excluding scalp).
  • Disease severity graded as mild to severe according to vIGA-AD (i.e. vIGA-AD ≥2) at screening and baseline.

Key Exclusion Criteria:

  • AD lesion(s) on scalp at screening and/or baseline.
  • Active dermatologic conditions that may confound the diagnosis of AD or would interfere with assessment of treatment, such as scabies, cutaneous lymphoma, rosacea, urticaria, or psoriasis.
  • Known active allergic or irritant contact dermatitis that is likely to interfere with the assessment of severity of AD.
  • Use of tanning beds or phototherapy within 4 weeks prior to baseline.
  • Systemic treatment with /modulating drugs or within 4 weeks prior to baseline or 3 or more bleach baths any week within 4 weeks prior to baseline.
  • Treatment with topical corticosteroids, topical calcineurin inhibitors, topical phosphodiesterase-4 inhibitors, or oral antibiotics within 2 weeks prior to baseline.
  • Change in systemic antihistamine therapy within 2 weeks prior to baseline i.e. the subjects must not start antihistamine treatment or change the current dosage regime within 2 weeks prior to baseline.
  • Receipt of within 4 weeks prior to baseline.
  • Treatment with any marketed or biologic agents within 6 months or 5 half-lives prior to baseline, or until cell counts return to normal, whichever is longer.
  • History of any active skin infection within 1 week prior to baseline.
  • infection (systemic infection or serious skin infection requiring parenteral treatment) within 4 weeks prior to baseline.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
251 participants (actual)

Study arms

  • Experimental
    Delgocitinib cream 1 mg/g

    Delgocitinib cream applied twice daily for 8 weeks

    Drug: Delgocitinib cream

  • Experimental
    Delgocitinib cream 3 mg/g

    Delgocitinib cream applied twice daily for 8 weeks

    Drug: Delgocitinib cream

  • Experimental
    Delgocitinib cream 8 mg/g

    Delgocitinib cream applied twice daily for 8 weeks

    Drug: Delgocitinib cream

  • Experimental
    Delgocitinib cream 20 mg/g

    Delgocitinib cream applied twice daily for 8 weeks

    Drug: Delgocitinib cream

  • Placebo comparator
    Delgocitinib cream vehicle

    Delgocitinib cream vehicle applied twice daily for 8 weeks

    Drug: Delgocitinib cream vehicle

Interventions

  • Cream for topical application

    Also known as: LEO 124249 cream

  • DrugDelgocitinib cream vehicle

    The cream vehicle is similar to the delgocitinib cream except that it does not contain any active ingredient.

    Also known as: LEO 124249 cream vehicle

06

What researchers measure

Primary outcomes

  1. Change From Baseline (Week 0) to Week 8 in Eczema Area and Severity Index (EASI) Score.

    EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe or more extensive condition. The multiple comparison procedure - modelling (MCP-Mod) approach was used to guide dose selection. Mixed Model for Repeated Measurements (MMRM) analysis was used to determine the difference in the continuous endpoint between the active delgocitinib doses and delgocitinib cream vehicle.

    Time frame: Week 0 to Week 8

Secondary outcomes

  1. Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) Score of 0 (Clear) or 1 (Almost Clear) With ≥2-step Improvement (vIGA-AD TS) From Baseline to Week 8.

    vIGA-AD is an instrument used in clinical trials to assess the subject's global disease severity and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). The multiple comparison procedure - modelling (MCP-Mod) approach was used to guide dose-selection. Cochran-Mantel-Haenszel analysis was used to determine the difference in response rates between the active delgocitinib cream doses and the delgocitinib cream vehicle.

    Time frame: Week 0 to Week 8

  2. EASI75 at Week 8

    EASI75 is defined as at least 75% reduction in EASI from baseline.

    Time frame: Week 0 to Week 8

  3. Time to vIGA-AD TS

    The time to vIGA-AD TS response is defined as the time from baseline to first assessment of a vIGA-AD score of 0 (Clear) or 1 (Almost Clear) with ≥2-step improvement

    Time frame: Week 0 to Week 8

07

Results

Posted Jul 8, 2021

Participant flow

251 participants from 31 sites in 3 countries (U.S., Canada and Australia) were randomised in this trial. The first participant was screened on 29-Nov-2018 and the last participant completed the trial on 19-May-2020.

Participant flow — Overall Study
MilestoneDelgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
Started4950505250
Completed3844444636
Not completed1166614
Withdrew: Lack of efficacy21202
Withdrew: Adverse event22106
Withdrew: Withdrawal by subject41044
Withdrew: Lost to follow-up31221
Withdrew: Personal reasons00101
Withdrew: Covid-19 situation01000

Outcome measures

PrimaryChange From Baseline (Week 0) to Week 8 in Eczema Area and Severity Index (EASI) Score.

EASI is a validated measure used in clinical practice and clinical trials to assess the severity and extent of AD. The EASI is a composite index with scores ranging from 0 to 72, with higher values indicating more severe or more extensive condition. The multiple comparison procedure - modelling (MCP-Mod) approach was used to guide dose selection. Mixed Model for Repeated Measurements (MMRM) analysis was used to determine the difference in the continuous endpoint between the active delgocitinib doses and delgocitinib cream vehicle.

Time frame:
Week 0 to Week 8
Reported as:
Least squares mean · score on a scale
Change From Baseline (Week 0) to Week 8 in Eczema Area and Severity Index (EASI) Score.
score on a scaleDelgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
Change From Baseline (Week 0) to Week 8 in Eczema Area and Severity Index (EASI) Score.-5.0 ± 0.7-4.9 ± 0.7-5.8 ± 0.7-7.6 ± 0.7-1.9 ± 0.8
Statistical analysis
  • Delgocitinib Cream 1 mg/g vs Delgocitinib Cream 3 mg/g vs Delgocitinib Cream 8 mg/g vs Delgocitinib Cream 20 mg/g vs Delgocitinib Cream Vehicle · Multiple contrast test · p = <0.0001 (P-values were adjusted for multiple comparisons. Models with adjusted p-value of \<0.025 were stat. sign. diff. from a flat dose-response model. Model selected: Sigmoid Emax model)
  • Delgocitinib Cream 1 mg/g vs Delgocitinib Cream Vehicle · Mixed Models Analysis · p = <0.01 (The stat. test was not controlled for multiplicity. Data at visits following premature discont. of IMP or initiation of rescue med. were excluded from the analysis. Likewise for missing data due to COVID-19 pandemic.) · Mean difference (net): -3.1 · 95% CI -5.0 to -1.3
  • Delgocitinib Cream 3 mg/g vs Delgocitinib Cream Vehicle · Mixed Models Analysis · p = <0.05 (The stat. test was not controlled for multiplicity. Data at visits following premature discont. of IMP or initiation of rescue med. were excluded from the analysis. Likewise for missing data due to COVID-19 pandemic.) · Mean difference (net): -3.0 · 95% CI -4.8 to -1.2
  • Delgocitinib Cream 8 mg/g vs Delgocitinib Cream Vehicle · Mixed Models Analysis · p = <0.0001 (The stat. test was not controlled for multiplicity. Data at visits following premature discont. of IMP or initiation of rescue med. were excluded from the analysis. Likewise for missing data due to COVID-19 pandemic.) · Mean difference (net): -4.0 · 95% CI -5.8 to -2.1
  • Delgocitinib Cream 20 mg/g vs Delgocitinib Cream Vehicle · Mixed Models Analysis · p = <0.0001 (The stat. test was not controlled for multiplicity. Data at visits following premature discont. of IMP or initiation of rescue med. were excluded from the analysis. Likewise for missing data due to COVID-19 pandemic.) · Median difference (net): -5.7 · 95% CI -7.5 to -3.9
SecondaryValidated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) Score of 0 (Clear) or 1 (Almost Clear) With ≥2-step Improvement (vIGA-AD TS) From Baseline to Week 8.

vIGA-AD is an instrument used in clinical trials to assess the subject's global disease severity and is based on a 5-point scale ranging from 0 (clear) to 4 (severe). The multiple comparison procedure - modelling (MCP-Mod) approach was used to guide dose-selection. Cochran-Mantel-Haenszel analysis was used to determine the difference in response rates between the active delgocitinib cream doses and the delgocitinib cream vehicle.

Time frame:
Week 0 to Week 8
Reported as:
Count of participants · Participants
Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) Score of 0 (Clear) or 1 (Almost Clear) With ≥2-step Improvement (vIGA-AD TS) From Baseline to Week 8.
ParticipantsDelgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD) Score of 0 (Clear) or 1 (Almost Clear) With ≥2-step Improvement (vIGA-AD TS) From Baseline to Week 8.91415245
Statistical analysis
  • Delgocitinib Cream 1 mg/g vs Delgocitinib Cream 3 mg/g vs Delgocitinib Cream 8 mg/g vs Delgocitinib Cream 20 mg/g vs Delgocitinib Cream Vehicle · Multiple contrast test · p = <0.0001 (Data collected after premature discont. of IMP due to COVID-19 were set to missing Week 8. Data collected after premature discont. of IMP due to reasons unrelated to COVID-19 or due to initiation of rescue med. were imputed as non-responders.)P-values adj. for multiple comparisons. Models with adj. p-value \<0.025 were stat. sign. diff. from a flat dose-response model. Model: Linear model
  • Delgocitinib Cream 1 mg/g vs Delgocitinib Cream Vehicle · Cochran-Mantel-Haenszel · p = >0.05 (Data collected after premature discont. of IMP due to COVID-19 were set to missing Week 8. Data collected after premature discont. of IMP due to reasons unrelated to COVID-19 or due to initiation of rescue med. were imputed as non-responders.) · Risk difference (rd): 8.2 · 95% CI -5.6 to 21.9
  • Delgocitinib Cream 3 mg/g vs Delgocitinib Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.05 (Data collected after premature discont. of IMP due to COVID-19 were set to missing Week 8. Data collected after premature discont. of IMP due to reasons unrelated to COVID-19 or due to initiation of rescue med. were imputed as non-responders.) · Risk difference (rd): 19.3 · 95% CI 3.9 to 34.6
  • Delgocitinib Cream 8 mg/g vs Delgocitinib Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.05 (Data collected after premature discont. of IMP due to COVID-19 were set to missing Week 8. Data collected after premature discont. of IMP due to reasons unrelated to COVID-19 or due to initiation of rescue med. were imputed as non-responders.) · Risk difference (rd): 20.3 · 95% CI 5.4 to 35.2
  • Delgocitinib Cream 20 mg/g vs Delgocitinib Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.0001 (Data collected after premature discont. of IMP due to COVID-19 were set to missing Week 8. Data collected after premature discont. of IMP due to reasons unrelated to COVID-19 or due to initiation of rescue med. were imputed as non-responders.) · Risk difference (rd): 38.3 · 95% CI 22.3 to 54.3
SecondaryEASI75 at Week 8

EASI75 is defined as at least 75% reduction in EASI from baseline.

Time frame:
Week 0 to Week 8
Reported as:
Count of participants · Participants
EASI75 at Week 8
ParticipantsDelgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
EASI75 at Week 82021283310
Statistical analysis
  • Delgocitinib Cream 1 mg/g vs Delgocitinib Cream 3 mg/g vs Delgocitinib Cream 8 mg/g vs Delgocitinib Cream 20 mg/g vs Delgocitinib Cream Vehicle · Multiple contrast test · p = <0.0001 (Data collected after premature discont. of IMP due to COVID-19 were set to missing Week 8. Data collected after premature discont. of IMP due to reasons unrelated to COVID-19 or due to initiation of rescue med. were imputed as non-responders.)P-values were adj. for multiple comparisons. Models with adj. p-value \<0.025 were stat. sign. diff. from a flat dose-response model. Model:Emax model
  • Delgocitinib Cream 1 mg/g vs Delgocitinib Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.05 (Data collected after premature discont. of IMP due to COVID-19 were set to missing Week 8. Data collected after premature discont. of IMP due to reasons unrelated to COVID-19 or due to initiation of rescue med. were imputed as non-responders.) · Risk difference (rd): 19.7 · 95% CI 1.8 to 37.6
  • Delgocitinib Cream 3 mg/g vs Delgocitinib Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.05 (Data collected after premature discont. of IMP due to COVID-19 were set to missing Week 8. Data collected after premature discont. of IMP due to reasons unrelated to COVID-19 or due to initiation of rescue med. were imputed as non-responders.) · Risk difference (rd): 23.5 · 95% CI 5.8 to 41.2
  • Delgocitinib Cream 8 mg/g vs Delgocitinib Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.0005 (Data collected after premature discont. of IMP due to COVID-19 were set to missing Week 8. Data collected after premature discont. of IMP due to reasons unrelated to COVID-19 or due to initiation of rescue med. were imputed as non-responders.) · Risk difference (rd): 35.3 · 95% CI 17.5 to 53.2
  • Delgocitinib Cream 20 mg/g vs Delgocitinib Cream Vehicle · Cochran-Mantel-Haenszel · p = <0.0001 (Data collected after premature discont. of IMP due to COVID-19 were set to missing Week 8. Data collected after premature discont. of IMP due to reasons unrelated to COVID-19 or due to initiation of rescue med. were imputed as non-responders.) · Risk difference (rd): 45.4 · 95% CI 28.1 to 62.8
SecondaryTime to vIGA-AD TS

The time to vIGA-AD TS response is defined as the time from baseline to first assessment of a vIGA-AD score of 0 (Clear) or 1 (Almost Clear) with ≥2-step improvement

Time frame:
Week 0 to Week 8
Reported as:
Median · Days
Time to vIGA-AD TS
DaysDelgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
Time to vIGA-AD TS64 (42 to 64)NA (42 to NA)64 (28 to 64)44 (26 to NA)NA (56 to NA)
Statistical analysis
  • Delgocitinib Cream 1 mg/g vs Delgocitinib Cream Vehicle · Log Rank · p = >0.05 (The statistical test was not controlled for multiplicity.)
  • Delgocitinib Cream 3 mg/g vs Delgocitinib Cream Vehicle · Log Rank · p = >0.05 (vIGA-AD was reached in less than 50% of participants, therefore the median time was not estimable. The statistical test was not controlled for multiplicity.)
  • Delgocitinib Cream 8 mg/g vs Delgocitinib Cream Vehicle · Log Rank · p = >0.05 (The statistical test was not controlled for multiplicity)
  • Delgocitinib Cream 20 mg/g vs Delgocitinib Cream Vehicle · Log Rank · p = <0.001 (The statistical test was not controlled for multiplicity)

Adverse events

Collected over 10 weeks (from first application of IMP up until the last visit (safety follow-up visit)).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Delgocitinib Cream 1 mg/g0/49 (0%)1/49 (2%)12/49 (24.5%)
Delgocitinib Cream 3 mg/g0/50 (0%)1/50 (2%)11/50 (22%)
Delgocitinib Cream 8 mg/g0/50 (0%)0/50 (0%)8/50 (16%)
Delgocitinib Cream 20 mg/g0/51 (0%)0/51 (0%)12/51 (23.5%)
Delgocitinib Cream Vehicle0/50 (0%)1/50 (2%)11/50 (22%)
Most frequent serious events
Most frequent serious events
EventDelgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
AsthmaRespiratory, thoracic and mediastinal disorders1/490/500/500/510/50
Malignant melanomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/490/500/500/511/50
Hypertonic bladderRenal and urinary disorders0/491/500/500/510/50
Most frequent other events
Most frequent other events
EventDelgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream Vehicle
Upper respiratory tract infectionInfections and infestations5/493/506/506/514/50
Dermatitis atopicSkin and subcutaneous tissue disorders5/492/501/502/513/50
AcneSkin and subcutaneous tissue disorders0/494/500/501/510/50
Application site pruritusGeneral disorders0/491/501/500/513/50
HeadacheNervous system disorders2/491/501/503/511/50

Baseline characteristics

Number of subjects randomized

Age, Continuous
Age, Continuous(years)Delgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream VehicleTotal
Mean43.8 ± 16.138.5 ± 16.642.0 ± 17.437.4 ± 14.741.3 ± 19.640.5 ± 17.0
Sex: Female, Male
Sex: Female, Male(Participants)Delgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream VehicleTotal
Female3433323736172
Male151718151479
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Delgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream VehicleTotal
Hispanic or Latino5658125
Not Hispanic or Latino4444454449226
Unknown or Not Reported000000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Delgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream VehicleTotal
White2728232826132
Black or African American31154831
Asian12919151469
Native Hawaiian or other Pacific islander000011
American Indian or Alaska native000101
Other7234117
Region of Enrollment
Region of Enrollment(participants)Delgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream VehicleTotal
Canada15919151472
United States2329192425120
Australia111212131159
Baseline EASI score
Baseline EASI score(units on a scale)Delgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream VehicleTotal
Mean9.3 ± 5.210.9 ± 9.18.6 ± 4.69.9 ± 6.911.2 ± 7.310.0 ± 6.8
Baseline vIGA-AD score
Baseline vIGA-AD score(Participants)Delgocitinib Cream 1 mg/gDelgocitinib Cream 3 mg/gDelgocitinib Cream 8 mg/gDelgocitinib Cream 20 mg/gDelgocitinib Cream VehicleTotal
0 - Clear000000
1 - Almost clear000000
2 - Mild181818191790
3 - Moderate2728282829140
4 - Severe4445421
08

Study locations

31 sites
  • Leo Pharma Investigational Site
    Birmingham, Alabama 35209, United States
  • Leo Pharma Investigational Site
    Encino, California 91436, United States
  • Leo Pharma Investigational Site
    Los Angeles, California 90033, United States
  • Leo Pharma Investigational Site
    Los Angeles, California 90045, United States
  • Leo Pharma Investigational Site
    Rolling Hills Estates, California 90274-7604, United States
  • Leo Pharma Investigational Site
    Santa Ana, California 92701, United States
  • Leo Pharma Investigational Site
    Chicago, Illinois 60611, United States
  • Leo Pharma Investigational Site
    Detroit, Michigan 48202, United States
  • Leo Pharma Investigational Site
    New York, New York 10019, United States
  • Leo Pharma Investigational Site
    High Point, North Carolina 27262, United States
  • Leo Pharma Investigational Site
    Philadelphia, Pennsylvania 19104, United States
  • Leo Pharma Investigational Site
    Carlton, 3053, Australia
  • Leo Pharma Investigational Site
    Darlinghurst, 2010, Australia
  • Leo Pharma Investigational Site
    East Melbourne, 3002, Australia
  • Leo Pharma Investigational Site
    Hectorville, 5073, Australia
  • Leo Pharma Investigational Site 1
    Kogarah, 2217, Australia
  • Leo Pharma Investigational Site
    Kogarah, 2217, Australia
  • Leo Pharma Investigational Site
    Woolloongabba, 4102, Australia
  • Leo Pharma Investigational Site
    Calgary, Alberta T3A 2N1, Canada
  • Leo Pharma Investigational Site
    Edmonton, Alberta T5K 1X3, Canada
  • Leo Pharma Investigational Site
    Surrey, British Columbia V3R 6A7, Canada
  • Leo Pharma Investigational Site
    Winnipeg, Manitoba R3M 3Z4, Canada
  • Leo Pharma Investigational Site
    Fredericton, New Brunswick E3B 1G9, Canada
  • Leo Pharma Investigational Site
    Mississauga, Ontaria L5H 1G9, Canada
  • Leo Pharma Investigational Site
    Barrie, Ontario L4M 7G1, Canada
  • Leo Pharma Investigational Site
    Markham, Ontario L3P 1X2, Canada
  • Leo Pharma Investigational Site
    Peterborough, Ontario K9J 5K2, Canada
  • Leo Pharma Investigational Site
    Richmond Hill, Ontario L4C 9M7, Canada
  • Leo Pharma Investigational Site
    Toronto, Ontario M2M 4J5, Canada
  • Leo Pharma Investigational Site
    Toronto, Ontario M2W 2N2, Canada
  • Leo Pharma Investigational Site
    Toronto, Ontario M3H 5Y8, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2018 to primary completion in May 2020, 16 months.

Results were first posted in Jul 2021, 1 year 1 month after primary completion.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 16 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2018
First posted
Oct 31, 2018
StartActual
Dec 28, 2018
Primary completionActual
May 19, 2020
CompletionActual
May 19, 2020
Results first posted
Jul 8, 2021
Last update
Mar 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03725722
Lead sponsor
LEO Pharma
Responsible party
Sponsor
First posted
Oct 31, 2018
Start date
Dec 28, 2018
Primary completion
May 19, 2020
Completion
May 19, 2020
Results posted
Jul 8, 2021
Last update
Mar 12, 2025

Study contacts

Medical Expert
study director · LEO Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Delgocitinib

Start the discussion